{
    "clinical_study": {
        "@rank": "99136", 
        "arm_group": [
            {
                "arm_group_label": "ambrisentan and theophylline", 
                "arm_group_type": "Experimental", 
                "description": "ambrisentan (5mg) once daily for 2 consecutive days theophylline (400mg) once daily for 2 consecutive days"
            }, 
            {
                "arm_group_label": "placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "matched placebo tablets wil be given at the same time to the comparison group as the medications to the experimental group"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is being conducted to determine the effectiveness of using two FDA approved\n      medications in concert to reduce the likelihood of sickness due to low oxygen levels and to\n      reduce the decrement in physical performance at higher elevations.  The investigators\n      hypothesize that this drug combination will reduce the symptoms of acute mountain sickness\n      and improve exercise performance at high altitude compared to placebo."
        }, 
        "brief_title": "Drug Combination on Exercise Performance at High Altitude", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "condition": "Acute Mountain Sickness", 
        "condition_browse": {
            "mesh_term": "Altitude Sickness"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  healthy males\n\n        Exclusion Criteria:\n\n          -  VO2max below 45ml/kg/min\n\n          -  currently taking any medication"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01902758", 
            "org_study_id": "UM82-13", 
            "secondary_id": "N66001-10-C-2134"
        }, 
        "intervention": [
            {
                "arm_group_label": "ambrisentan and theophylline", 
                "description": "n/a", 
                "intervention_name": "ambrisentan and theophylline", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "placebo", 
                "description": "placebo for comparison group", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Theophylline"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "exercise performance", 
        "lastchanged_date": "February 26, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Missoula", 
                    "country": "United States", 
                    "state": "Montana", 
                    "zip": "59812"
                }, 
                "name": "Montana Center for Work Physiology and Exercise Metabolism"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Enhancing Physical Performance and Mitigating Acute Mountain Sickness Via Pharmaceutical Intervention While at Altitude", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Time (minutes) to complete 2 miles on a treadmill", 
            "safety_issue": "No", 
            "time_frame": "upon arrival to high altitude"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01902758"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Montana", 
            "investigator_full_name": "Brent Ruby", 
            "investigator_title": "Director of the Montana Center for Work Physiology and Exercise Metabolism", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Time (minutes) to complete 2 miles on a treadmill", 
            "safety_issue": "No", 
            "time_frame": "24 hours after primary outcome measure"
        }, 
        "source": "University of Montana", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Montana", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}